The virus spreads where people are in close contact.
In late July 2022, the World Health Organization elevated monkeypox to its highest alert status as a disease long confined to Africa spread to over 16,000 people across 75 countries in a matter of weeks. The declaration is less a signal of catastrophe than a call to coordination — an acknowledgment that a virus, given the right conditions of travel and proximity, can quietly cross every border we imagine protects us. With tools available but systems underfunded, the question is not whether humanity has the means to respond, but whether it has the will to deploy them in time.
- A virus historically contained to Africa has reached 16,000 cases across 75 countries in under three months, forcing the WHO to trigger its most serious emergency classification.
- Europe faces a high-threat designation as transmission accelerates there, while sexual health clinics — the frontline of response — are stretched thin after years of underfunding.
- Unlike COVID-19, monkeypox does not spread through the air, and most patients recover on their own, but the speed of its global expansion has alarmed officials who fear it could entrench itself in new regions permanently.
- Two vaccines exist and an approved antiviral is available, yet production capacity and distribution constraints mean high-risk populations are not yet fully protected.
- The emergency declaration is designed to unlock global coordination on testing, vaccines, and treatment — but whether strained health systems can execute that response remains the defining uncertainty.
On July 26, 2022, WHO Director-General Tedros Adhanom Ghebreyesus declared monkeypox a global health emergency — the organization's highest alert level. What had begun as a handful of cases in the United Kingdom in early May had grown into more than 16,000 confirmed infections across 75 countries, with five deaths, all in Africa where the virus is endemic.
Monkeypox spreads through close skin-to-skin contact, contaminated clothing, or bedding. It produces fever, body aches, and distinctive lesions that resolve within weeks. Crucially, it lacks the airborne efficiency that made COVID-19 so devastating. Outside Africa, cases have concentrated almost entirely among men who have sex with men. The WHO rated global risk as moderate but raised Europe's threat level to high, reflecting the continent's rapid case acceleration.
The emergency designation exists to mobilize resources. Two vaccines are available — an older formulation with serious side effects and a newer one from Bavarian Nordic, which can produce 30 million doses annually and is expanding capacity. An antiviral called tecovirimat holds approval for related diseases in both the U.S. and EU, and most patients recover without it.
Beneath these available tools, however, lies a structural problem. Sexual health clinics bearing the weight of the response have been chronically underfunded. Scientists are still uncertain what ignited the initial outbreak or whether the virus has changed. The emergency declaration signals urgency — but the real measure of this moment will be whether the world's health systems, already worn, can find the coordination the crisis demands.
On Saturday, July 26, the World Health Organization's director-general Tedros Adhanom Ghebreyesus made the declaration that public health officials had been bracing for: monkeypox had reached the organization's highest alert level. The virus, first identified in monkeys and historically confined to Africa where it remains endemic, had broken through into the wider world. What began as a handful of cases reported in the United Kingdom in early May had metastasized into something far larger—more than 16,000 confirmed cases across 75 countries, with five deaths recorded, all of them in Africa.
Monkeypox spreads through close contact with an infected person, particularly through skin-to-skin contact with someone displaying an active rash, or through contaminated clothing and bedding. The disease typically produces fever, body aches, and distinctive pus-filled lesions that resolve within two to four weeks. It is not the respiratory threat that COVID-19 proved to be. Dr. Martin Hirsch of Massachusetts General Hospital noted the crucial difference: monkeypox lacks the airborne transmission efficiency that made the coronavirus so devastating. The fatality rate in previous African outbreaks of the strain now circulating globally has hovered around 1 percent, though the current outbreak outside endemic regions appears to be claiming fewer lives, partly because countries with stronger healthcare systems can manage severe cases more effectively.
Outside of Africa, the outbreak has concentrated almost exclusively among men who have sex with men. The WHO has assessed the global risk as moderate, but elevated Europe's threat level to high—a distinction that reflects both the density of cases on that continent and the speed at which transmission has accelerated there. Health officials from multiple countries had pressed the WHO to issue this emergency declaration, arguing that the rapid escalation of cases and the possibility that monkeypox could become established in new regions demanded the organization's most forceful response.
The emergency designation serves a practical purpose: it mobilizes global resources and coordination on testing, vaccine production, and treatment distribution. Two vaccine options exist. An older formulation called ACAM2000, manufactured by Emergent Biosolutions, has seen limited uptake because of serious side effects. Bavarian Nordic produces a newer vaccine and says it can manufacture 30 million doses annually across all its products, though the company has engaged a U.S. contract manufacturer to expand monkeypox vaccine capacity specifically. Health authorities have begun offering vaccines to high-risk individuals and to people who have had recent close contact with confirmed cases.
For treatment, an antiviral called tecovirimat—marketed as TPOXX and produced by SIGA Technologies—carries approval for smallpox in both the United States and European Union, with European authorization explicitly extended to monkeypox and cowpox. Most patients recover without pharmaceutical intervention, though doctors may administer fluids and treat secondary bacterial infections as needed.
Yet beneath the availability of medical tools lies a structural vulnerability. Sexual health clinics, which sit at the frontline of the current response, have suffered from years of underfunding and are ill-equipped to contain further spread. Scientists remain uncertain what triggered the initial cluster of cases or whether the virus itself has undergone any meaningful change. Experts point to increased global travel and climate change as general accelerants of viral emergence and transmission. The emergency declaration signals urgency, but the real test will be whether the world's health systems, many already strained, can mount the coordinated response the moment demands.
Notable Quotes
COVID is spread by respiratory route and is highly infectious. This doesn't appear to be the case with monkeypox.— Dr. Martin Hirsch, Massachusetts General Hospital
Years of financial neglect has left sexual health clinics ill-prepared to curb further spread.— Infectious disease experts cited in reporting
The Hearth Conversation Another angle on the story
Why did the WHO wait until cases hit 16,000 before declaring an emergency? Couldn't they have acted sooner?
The declaration came when the trajectory became undeniable—a handful of cases in May to over 16,000 by late July. But you're right to ask. Health officials from several countries were pushing for this declaration earlier, sensing the outbreak was accelerating beyond Africa's borders. The WHO moves cautiously, but the speed of spread forced their hand.
Is this actually dangerous, or is the media making it sound worse than it is?
It's genuinely less severe than COVID-19. The virus spreads through close contact, not air. Most people recover in two to four weeks with mild symptoms. But "less dangerous than COVID" is a low bar. Five people have died. And the real danger isn't the virus itself—it's that we've let sexual health clinics deteriorate so badly they're unprepared to respond.
Why is the outbreak concentrated among men who have sex with men?
That's where transmission is happening most readily right now, through close contact networks. It's not that the virus discriminates. It's epidemiology—it spreads where people are in close contact. But that detail matters because it shapes where public health resources need to go, and it shapes how the message gets received.
Can we actually make enough vaccine?
Bavarian Nordic says 30 million doses a year across all their products. They're bringing in help to scale up monkeypox specifically. But that's production capacity. Distribution is another problem entirely. And the older vaccine has serious side effects, so uptake has been weak. We have tools. Whether we deploy them effectively is the open question.
What happens next?
The emergency declaration is meant to spur action—coordination on testing, vaccine distribution, treatment access. But the real bottleneck is the sexual health clinics that are supposed to be managing this. They've been starved of resources for years. Without fixing that, even good vaccines and antivirals won't reach the people who need them fast enough.